Vagus Nerve Stimulation — Cost, Top Hospitals & Success Rates | MyMedicPlus

Vagus nerve stimulation (VNS) is a neuromodulation therapy that delivers mild, regular electrical impulses to the brain via the vagus nerve — the longest cranial nerve, running from the brainstem through the neck and into the abdomen. By modulating the nerve's signalling, VNS can reduce abnormal electrical activity in the brain, improving seizure control and mood regulation.

The vagus nerve (cranial nerve X) carries approximately 80% afferent (sensory) fibres from the body to the brain, including projections to the nucleus tractus solitarius, locus coeruleus, and limbic structures. Electrical stimulation of these pathways alters neurotransmitter release — particularly norepinephrine, serotonin, and GABA — producing anticonvulsant and antidepressant effects.

The most established form of VNS involves a surgically implanted pulse generator (a device roughly the size of a large watch) placed under the skin of the left chest wall, with a coiled lead wrapped around the left vagus nerve in the neck. The device is programmed externally by a neurologist and delivers intermittent stimulation continuously. Patients also receive a handheld magnet to trigger additional stimulation at the onset of a seizure or depressive episode.

Newer non-invasive VNS (nVNS) devices — including transcutaneous auricular VNS (taVNS) and cervical nVNS (gammaCore) — stimulate vagal branches through the skin without surgery and are being studied across a broad range of conditions. The gammaCore device is FDA-cleared for cluster headache and migraine prevention.

Vagus nerve stimulation has FDA approval for two primary neuropsychiatric conditions, with a growing body of evidence supporting its use in additional disorders:

FDA-Approved Indications

• Drug-resistant epilepsy (adjunctive therapy): VNS is indicated as an adjunctive treatment for partial-onset (focal) seizures in patients aged 4 years and older who have failed two or more appropriate antiseizure medications (ASMs). It does not cure epilepsy but reduces seizure frequency in the majority of implanted patients. After 3 years of VNS therapy, approximately 50–60% of patients achieve a >50% reduction in seizure frequency.
• Treatment-resistant depression (TRD): VNS is FDA-approved as an adjunctive long-term treatment for chronic or recurrent major depressive disorder in adults who have failed four or more adequate antidepressant treatments. Benefits accumulate gradually — meaningful improvement is typically seen after 6–12 months of continuous stimulation.

Investigational and Off-Label Uses

• Cluster headache and migraine: Non-invasive cervical VNS (gammaCore) is FDA-cleared for acute and preventive treatment of cluster headache and migraine.
• Post-stroke motor rehabilitation: Paired VNS with physical therapy has shown significant improvements in upper limb motor function in stroke survivors in Phase III trials (VIVISTIM pivotal trial).
• Post-traumatic stress disorder (PTSD): Early-phase clinical trials are investigating VNS as an augmentation strategy for PTSD.
• Inflammatory conditions: Bioelectronic medicine research is exploring VNS for rheumatoid arthritis, inflammatory bowel disease, and sepsis via the cholinergic anti-inflammatory pathway.
• Lennox-Gastaut syndrome and other epilepsy syndromes: VNS is used across multiple epilepsy types beyond focal epilepsy, including generalised epilepsies in paediatric patients.

Patient selection for VNS implantation requires comprehensive neurological or psychiatric evaluation. Criteria vary by indication:

For Drug-Resistant Epilepsy

• Diagnosis of drug-resistant epilepsy — defined as failure to achieve sustained seizure freedom with two adequately dosed and tolerated ASMs (as per ILAE 2010 definition)
• Age 4 years or older; VNS is used in paediatric patients including infants in selected cases
• Seizures not amenable to curative resective surgery (e.g., no clearly localised resectable focus, or patient declines resection after multidisciplinary team evaluation)
• Patients with Lennox-Gastaut syndrome, tuberous sclerosis complex, or Dravet syndrome who are not candidates for corpus callosotomy

For Treatment-Resistant Depression

• Adults with major depressive disorder (MDD) or bipolar I/II disorder with a current major depressive episode
• Failure of at least four adequate antidepressant treatments (across different medication classes, psychotherapy, or ECT)
• Medically stable without active suicidality that precludes outpatient management

Contraindications

• Bilateral or left cervical vagotomy (no vagus nerve to stimulate)
• Pacemaker or other implantable medical devices that may experience electromagnetic interference — requires specialist cardiac review
• Active sleep apnoea (VNS can worsen hypopnoea during sleep; sleep study required if suspected)
• Pregnancy — safety not established; implantation deferred until after delivery
• Previous significant left-sided neck surgery or tumour in the cervical region that precludes lead placement
• Active progressive neurological disease (relative contraindication; individualised assessment required)

VNS therapy is available in implanted and non-invasive forms, with different indications and evidence bases:

1. Implanted VNS — Standard Pulse Generator (LivaNova SenTiva, Model 1000)

The current generation LivaNova SenTiva generator offers closed-loop stimulation via an integrated cardiac sensor. The device detects ictal tachycardia (heart rate increase associated with many seizures) and automatically increases stimulation at seizure onset, improving responsiveness. Typical initial settings: output current 0.25–1.5 mA, frequency 20–30 Hz, pulse width 250–500 microseconds, with ON time 30 seconds and OFF time 5 minutes. Settings are titrated over months by the neurologist via a programming wand.

2. Implanted VNS — AspireSR (Closed-Loop, older model)

The predecessor to the SenTiva; widely implanted since 2015. A 2020 prospective registry study (CORE-VNS) confirmed that closed-loop sensing was associated with greater seizure reduction compared to standard stimulation alone.

3. Non-invasive Cervical VNS (nVNS) — gammaCore

A handheld device applied to the neck over the carotid triangle. Delivers 2-minute stimulation sessions through the skin to the cervical vagus nerve branches. FDA-cleared for cluster headache (acute and preventive) and migraine prevention. No surgery required. Limitations: less potent than implanted VNS; requires patient self-administration 2–3 times daily.

4. Transcutaneous Auricular VNS (taVNS)

Stimulates the auricular branch of the vagus nerve (Arnold's nerve) at the ear using surface electrodes. Used in research settings and available in some European countries (e.g., NEMOS device). Under investigation for epilepsy, depression, and stroke rehabilitation.

5. Responsive Neurostimulation (RNS) and Deep Brain Stimulation (DBS)

Not technically VNS, but alternative neurostimulation modalities offered by epilepsy programmes. RNS (NeuroPace) delivers responsive stimulation directly to the seizure focus and may be considered when a focal resectable zone exists. DBS of the anterior nucleus of the thalamus (ANT-DBS) is FDA-approved for drug-resistant focal epilepsy and is an alternative to VNS.

Decades of real-world use and clinical trial data support the following outcomes from VNS therapy:

Epilepsy Outcomes

• Seizure reduction: Long-term registry data show approximately 50% of patients achieve >50% seizure reduction after 3 years (E-04 and E-05 trials; VNS Therapy Patient Outcome Registry). Roughly 5–10% of patients become seizure-free.
• Progressive benefit: Unlike medications where tolerance can develop, VNS benefit tends to increase over time. Patients who respond partially at 1 year often show greater improvement at 2–5 years.
• Improved seizure severity: Many patients report shorter, less severe seizures even when seizure frequency does not decrease significantly.
• Mood and cognitive benefits: Independent of seizure control, VNS often improves alertness, mood, and quality of life — relevant given high rates of depression in epilepsy.

Depression Outcomes

• The D-23 long-term follow-up study found that 27% of VNS-treated patients with TRD achieved remission at 5 years, compared with 13% in the treatment-as-usual group — a significant difference given the severity and chronicity of TRD.
• Response rates (defined as >50% improvement in depression scale scores) reach approximately 40–50% at 2 years of continuous stimulation.

Quality of Life and Safety

• Health-related quality of life (HRQOL) improves significantly across both epilepsy and depression populations
• No systemic drug interactions; no cognitive side effects; no sedation — advantages over additional antiseizure medications
• Adjunctive — does not replace medication but reduces medication burden in many patients

VNS therapy has a well-characterised safety profile built over more than two decades of use. Risks fall into surgical and stimulation-related categories:

Surgical Risks (Implantation)

• Infection: Device or wound infection occurs in approximately 1–3% of implantations and may require device explanation
• Lead complications: Lead fracture, dislodgement, or fibrous encapsulation of the helical electrode may require reoperation
• Nerve injury: Left vagus nerve injury is rare (<1%) but could cause hoarseness, dysphagia, or bradycardia if the cardiac branch is inadvertently affected
• Haematoma at device site: Accumulation of blood under the chest incision, usually managed conservatively

Stimulation-Related Side Effects

• Voice change/hoarseness: The most common side effect, affecting 50–60% of patients. Characteristically occurs only during ON cycles and resolves during OFF cycles; usually improves with output current reduction.
• Cough and throat clearing: Transient cough or throat sensation during stimulation in approximately 20–30% of patients; typically mild and diminishes over time
• Dyspnoea on exertion: Shortness of breath during vigorous exercise, particularly during stimulation ON cycles; uncommon at standard settings
• Paraesthesia: Tingling or sensation in the throat or neck during stimulation cycles
• Sleep-disordered breathing: VNS can increase the frequency of apnoea or hypopnoea events during sleep; a preoperative sleep study is recommended if sleep apnoea is suspected

Other Considerations

• MRI compatibility: Modern VNS devices (SenTiva) are MRI-conditional under specific scan parameters; older devices may have more restrictions. Inform all radiology teams of the implanted device before any MRI.
• VNS does not prevent all seizures; the patient should not drive until seizure-free per local regulatory criteria

Ongoing management of VNS therapy involves regular neurological or psychiatric review, device programming, and battery monitoring:

Initial Programming (First 6 Months)

• Device is typically activated 2 weeks after implantation, starting at low output current (0.25 mA) to minimise side effects
• Current is incrementally increased at each programming visit (every 4–8 weeks) guided by side-effect tolerance and clinical response
• Target maintenance settings are usually reached by 3–6 months; subsequent programming visits become less frequent

Long-Term Monitoring

• Annual or semi-annual neurologist/psychiatrist review with device interrogation to assess stimulation data, battery status, and clinical outcomes
• Diary-keeping of seizure frequency or depressive episode duration is valuable for assessing response over time
• Magnet use reviewed — patients are trained to hold the hand magnet over the device during a seizure aura or at the onset of seizure to trigger an extra stimulation burst

Battery Replacement

• Battery lifespan ranges from 6 to 12+ years depending on stimulation parameters and device model
• Replacement is a minor surgical procedure under local anaesthesia (or light sedation) requiring only replacement of the pulse generator; the lead electrode in the neck is not disturbed
• Day surgery or short hospital stay; recovery is rapid

Emergency Considerations

• If a seizure occurs during MRI or medical procedure, the device can be turned off temporarily with the programming wand or permanently disabled with the magnet
• Patients should carry a VNS identification card indicating device brand, model, and settings for emergency healthcare providers

VNS is among the more expensive neurological interventions due to device cost, surgical fees, and the need for long-term specialist follow-up. Cost components include:

• Device cost: The VNS pulse generator and lead kit costs approximately USD $10,000–$20,000 at list price. Hospital purchasing contracts significantly reduce this cost in high-volume centres.
• Surgical fees: Neurosurgeon and anaesthetist fees for implantation; approximately USD $3,000–$8,000 in the United States, substantially lower in countries with regulated surgical fee schedules.
• Hospital stay: Implantation is generally performed as day surgery or with 1 overnight stay. Longer stays increase cost.
• Programming visits: Neurology programming visits every 4–8 weeks in the first year; annually thereafter. Each visit has an associated specialist consultation fee.
• Battery replacement: Every 6–12 years; minor surgical procedure with device-only cost.

Country-Specific Total Cost Estimates (Including Device and Surgery)

In countries with universal or statutory health insurance, VNS for drug-resistant epilepsy is usually funded when criteria are met. TRD coverage varies widely — private payers in the US historically have had inconsistent coverage; CMS expanded Medicare coverage in 2023 for TRD VNS.

VNS is one of several options for patients with drug-resistant epilepsy or treatment-resistant depression. The choice between alternatives depends on seizure/symptom characteristics, anatomy, and patient preference:

For Drug-Resistant Epilepsy

• Resective surgery: For patients with a clearly localised seizure focus confirmed by presurgical evaluation (MRI, EEG, PET, MEG), surgical resection (e.g., anterior temporal lobectomy) offers the highest chance of seizure freedom — approximately 60–70% for temporal lobe epilepsy. VNS is typically considered when no resectable focus exists or when surgery is declined.
• Deep brain stimulation (DBS) of the anterior nucleus of thalamus (ANT-DBS): FDA-approved for drug-resistant focal epilepsy in adults; may be preferred when focal onset is established but resection is not possible. The SANTE trial demonstrated 40% median seizure reduction at 2 years.
• Responsive neurostimulation (RNS): NeuroPace RNS System detects seizure activity and delivers closed-loop stimulation directly to the seizure focus. Preferred when a focal cortical or mesial temporal target can be identified.
• Ketogenic diet: High-fat, low-carbohydrate diet producing ketosis has Level A evidence for drug-resistant epilepsy, particularly in children. Effective in some patients but adherence is challenging.
• Additional antiseizure medications: Though by definition these patients have failed two medications, additional trials of newer agents (lacosamide, brivaracetam, cenobamate) may be warranted before device implantation.

For Treatment-Resistant Depression

• Electroconvulsive therapy (ECT): The gold-standard acute treatment for severe TRD with rapid onset; VNS is considered for maintenance after ECT response.
• Transcranial magnetic stimulation (TMS/rTMS): Non-invasive; FDA-cleared for MDD. Less effective than VNS for severe chronic TRD but avoids surgery.
• Ketamine/esketamine (Spravato): Rapid-acting antidepressant; FDA-approved for TRD. Acute benefit but maintenance regimens required.
• Deep brain stimulation for depression: Investigational; targeting subgenual cingulate cortex (Area 25). Large pivotal trials have shown mixed results.